Radioimmunotherapy: A Specific Treatment Protocol for Cancer by Cytotoxic Radioisotopes Conjugated to Antibodies

Table 2

Anticancer RITs reported in this century.

Cancer	Target molecule	mAb	Radioisotope	Subject	Reference
Direct method
Non-Hodgkin lymphoma	CD20	Ibritumomab	Y-90	Human (in clinical use)	[33]
		Tositumomab	I-131	Human (in clinical use)	[31, 33, 34]
		Rituximab	I-131	Human (phase II)	[35–37]
	CD22	Epratuzumab	Y-90	Human (phase II)	[32, 38, 39]
Myeloid leukemia	CD33	Lintuzumab	Bi-213	Human (phase II)	[40, 41]
Raji B-lymphoma	CD74	L243	Ga-67	Cell	[42]
Colorectal cancer	Carcinoembryonic antigen (CEA)	cT84.66	Y-90	Human (phase I)	[54, 55]
	A33 glycoprotein	huA33	At-211	Mouse xenograft model	[62]
Colorectal cancer (liver metastases)	CEA	F6 F(ab′)2	I-131	Human (phase II)	[58]
	CEA-related cell adhesion molecule	Labetuzumab	I-131	Human (phase II)	[63, 64]
Gastrointestinal cancer	CEA	A5B7	I-131	Human (phase I)	[48]
Breast cancer	HER-2	Trastuzumab	Y-90	Mouse xenograft model	[66]
			Pb-212	Human (phase I)	[68]
		NLS-trastuzumab	In-111	Cell	[67]
Ovarian cancer	Na-dependent phosphate transporter	MX35 F(ab′)2	At-211	Human (phase I)	[73]
Prostate cancer	MUC-1	m170	Y-90	Human (phase I)	[75, 76]
		J591	Y-90	Human (phase I)	[77]
			Lu-177	Human (phase I)	[78]
			Bi-213	Mouse xenograft model	[79]
Multiple myeloma	CD138	Anti CD138 Ab	Bi-213	Mouse xenograft model	[20]
Indirect method
Non-Hodgkin lymphoma	CD20	TF4 (HSG)	Y-90	Mouse xenograft model	[100, 101]
		1F5(scFv)4 (streptavidin)	Y-90	Mouse xenograft model	[102]
	CD20, CD22, HLA-DR	Corresponding Abs (streptavidin)	Y-90	Mouse xenograft model	[103]
Colon cancer	CEA	hBS14 (HSG)	Y-90	Mouse xenograft model	[96]
		MN14 (MORF)	Re-188	Mouse xenograft model	[98]
	Ep-CAM	NR-LU-10 (HSG)	Y-90	Human (phase II)	[87]
Gastrointestinal cancer	TAG-72	CC49-(scFv)4 (streptavidin)	Y-90	Human (phase I)	[104]
Glioma	Tenascin	BC4 (biotin)	Y-90	Human (phase II)	[105]